• If you are wondering whether Edwards Lifesciences stock at around US$81 is starting to look attractively priced, or still demanding a premium, this article breaks down what the current valuation really implies for you.
• Over the last week the stock is up 1.8%; over the last month it is up 4.1%. Yet year to date it is still down 4.6%, and the return over the last 5 years is a decline of 13.6%. This can leave investors questioning whether the recent rebound has more room to run or is just a pause in a longer weak patch.
• Recent coverage around Edwards Lifesciences has focused on its position in medical devices and how sentiment has shifted as investors reassess growth expectations and risk. These headlines help explain why the stock has delivered a 4.3% gain over the last year but is still showing a 7.4% decline over 3 years.
• On Simply Wall St’s valuation checks, Edwards Lifesciences scores just 1 out of 6 for being undervalued. Next you will see how that score looks under different valuation approaches and then finish with a broader way to think about what the market is really pricing in.

Edwards Lifesciences scores just 1/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Edwards Lifesciences Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes estimates of the cash a company could generate in the future and discounts those cash flows back to today, to arrive at an estimate of what the stock might be worth now.

For Edwards Lifesciences, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections. The latest twelve month Free Cash Flow is about $1,048.6m. Analysts provide explicit forecasts for several years, and Simply Wall St then extrapolates the later years, with projected Free Cash Flow reaching around $2.9b by 2035 according to the supplied ten year projection set.

Using these projections, the DCF model arrives at an estimated intrinsic value of about $89.48 per share. Compared with the recent share price around $81, the model implies the stock trades at roughly a 9.0% discount to this estimate, which is a relatively small gap and can reasonably be viewed as close to fair value.

Result: ABOUT RIGHT

Edwards Lifesciences is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.

Approach 2: Edwards Lifesciences Price vs Earnings

For profitable companies like Edwards Lifesciences, the P/E ratio is a useful way to see how much you are paying for each dollar of earnings. It quickly shows how the market is weighing earnings quality against expectations and risk.

A higher P/E can reflect stronger expected growth or lower perceived risk, while a lower P/E can point to more modest expectations or higher uncertainty. So the question is not whether a P/E is high or low in isolation, but whether it makes sense given those factors.

Edwards Lifesciences currently trades on a P/E of about 43.6x, compared with the Medical Equipment industry average of around 25.2x and a peer average of roughly 24.0x. Simply Wall St’s Fair Ratio for the stock is 28.9x. This Fair Ratio is a proprietary estimate of what a reasonable P/E could be given the company’s earnings growth profile, profit margins, industry, market cap and risk characteristics.

The Fair Ratio offers a more tailored yardstick than a simple peer or industry comparison because it adjusts for company specific qualities rather than assuming all stocks deserve the same multiple.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Edwards Lifesciences Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so this is where Narratives come in, giving you a simple story that links your view on Edwards Lifesciences to forecast numbers and a fair value that you can compare with the current price.

A Narrative on Simply Wall St is your own storyline for a company, where you spell out what you think happens to revenue, earnings and margins, and the platform turns that into a fair value estimate that sits alongside the live share price to help you judge whether the stock currently looks expensive or cheap.

Because Narratives live on the Community page used by millions of investors and update automatically when new news, earnings or guidance appear, you can quickly see how fresh information feeds into your forecast and whether that changes your view about buying, holding or selling.

For Edwards Lifesciences, one investor might build a Narrative close to the high analyst price target of US$110.0 if they focus on product launches like TAVR, EVOQUE and Sapien M3. Another might lean toward the lower US$84.0 target if they put more weight on risks around tariffs, the JenaValve acquisition and competition in markets such as Japan.

Do you think there's more to the story for Edwards Lifesciences? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.